RS55585B1 - Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma - Google Patents

Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma

Info

Publication number
RS55585B1
RS55585B1 RS20170026A RSP20170026A RS55585B1 RS 55585 B1 RS55585 B1 RS 55585B1 RS 20170026 A RS20170026 A RS 20170026A RS P20170026 A RSP20170026 A RS P20170026A RS 55585 B1 RS55585 B1 RS 55585B1
Authority
RS
Serbia
Prior art keywords
syndrome
autism
fragile
methods
treating down
Prior art date
Application number
RS20170026A
Other languages
English (en)
Inventor
Randall L Carpenter
Kathryn Roberts
Mark F Bear
Original Assignee
Clinical Research Associates LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinical Research Associates LLC filed Critical Clinical Research Associates LLC
Publication of RS55585B1 publication Critical patent/RS55585B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Surgical Instruments (AREA)
RS20170026A 2006-11-22 2007-11-21 Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma RS55585B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86073306P 2006-11-22 2006-11-22
US156707P 2007-11-02 2007-11-02
PCT/US2007/024311 WO2008066750A1 (en) 2006-11-22 2007-11-21 Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism

Publications (1)

Publication Number Publication Date
RS55585B1 true RS55585B1 (sr) 2017-06-30

Family

ID=39272866

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170026A RS55585B1 (sr) 2006-11-22 2007-11-21 Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma

Country Status (16)

Country Link
US (6) US8143311B2 (sr)
EP (3) EP2083811B1 (sr)
JP (1) JP2010510314A (sr)
AU (1) AU2007325836B2 (sr)
CA (1) CA2670116C (sr)
CY (1) CY1118406T1 (sr)
DK (1) DK2083811T3 (sr)
ES (1) ES2610508T3 (sr)
HR (1) HRP20170027T1 (sr)
HU (1) HUE032743T2 (sr)
LT (1) LT2083811T (sr)
PL (1) PL2083811T3 (sr)
PT (1) PT2083811T (sr)
RS (1) RS55585B1 (sr)
SI (1) SI2083811T1 (sr)
WO (1) WO2008066750A1 (sr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2201950T (pt) * 2008-12-08 2017-01-31 Biocodex Compostos e métodos para tratar doenças do espetro do autismo
DK2395990T3 (en) 2009-02-12 2015-02-23 Univ Indiana Res & Tech Corp Material and methods for the treatment of developmental disorders comprising co-morbid and idiopathic autism
US8334287B2 (en) 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
WO2011053636A1 (en) * 2009-10-27 2011-05-05 Mount Sinai School Of Medicine Methods of treating psychiatric or neurological disorders with mglur antagonists
WO2011109398A2 (en) * 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2012009646A1 (en) * 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
US8946206B2 (en) 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
CA2874737A1 (en) 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Use of baclofen to treat insomnia
BR112015012506A2 (pt) * 2012-11-28 2017-07-11 Neuren Pharmaceuticals Ltd tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014128882A1 (ja) * 2013-02-21 2014-08-28 医療法人 和楽会 不安うつ病の治療薬
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
AU2014337504B2 (en) 2013-10-14 2020-01-30 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK 1-2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
CA2974091A1 (en) 2015-01-15 2016-07-21 Allaysis, Llc Intravenous baclofen formulations and treatment methods
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
WO2016132218A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of administering r-baclofen in an extended release dosage form
EP3324961A4 (en) 2015-07-17 2019-03-13 Ovid Therapeutics, Inc. METHOD FOR TREATING DEVELOPMENT DISORDERS WITH GABOXADOL
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10535243B2 (en) * 2016-10-28 2020-01-14 HBH Development LLC Target behavior monitoring system
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
US20210057078A1 (en) * 2018-01-18 2021-02-25 Cureapp, Inc. System, device, method, and program for treating disorder treatable by behavior modification
AU2019214891A1 (en) 2018-01-30 2020-08-20 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
USD970544S1 (en) * 2021-02-26 2022-11-22 Oracle International Corporation Display screen or portion thereof with icon or paper product with surface ornamentation
USD967184S1 (en) * 2021-02-26 2022-10-18 Oracle International Corporation Display screen or portion thereof with icon, or paper product with surface ornamentation
US11523984B1 (en) * 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
WO2023178183A1 (en) * 2022-03-16 2023-09-21 University Of Florida Research Foundation, Incorporated Combinatorial activation of gaba(b) and alpha-2 adrenergic receptors for treatment of stress induced depression

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
NO129043B (sr) 1968-02-16 1974-02-18 Fujisawa Pharmaceutical Co
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4411901A (en) 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
JPH0625181B2 (ja) 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
EP0385237B1 (en) 1989-03-03 1994-06-29 Dainippon Pharmaceutical Co., Ltd. 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
DE69021645T2 (de) 1989-05-19 1996-02-22 Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US6107025A (en) 1991-05-24 2000-08-22 Baylor College Of Medicine Diagnosis of the fragile X syndrome
US6180337B1 (en) 1991-05-24 2001-01-30 Baylor College Of Medicine Diagnosis of the fragile X syndrome
DE4243287A1 (de) 1992-06-19 1993-12-23 Basf Ag N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
DE4339702A1 (de) 1993-11-22 1995-05-24 Bayer Ag Verfahren zur Herstellung von harten Polyurethanschaumstoffen
EP0750621B1 (en) 1994-03-14 1999-07-21 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996015099A1 (en) 1994-11-09 1996-05-23 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
WO1997005109A1 (en) 1995-07-31 1997-02-13 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
EP0842176A1 (en) 1995-07-31 1998-05-20 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
GB9609976D0 (en) 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
AU3783497A (en) 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
FR2759366B1 (fr) 1997-02-11 1999-04-16 Centre Nat Rech Scient Composes constituant notamment des effecteurs de recepteurs du systeme nerveux central sensibles aux amino acides neuroexcitateurs, leur preparation et leurs applications biologiques
BR9809071A (pt) 1997-04-07 2000-08-01 Lilly Co Eli Agentes farmacológicos
WO1998053812A1 (en) 1997-05-27 1998-12-03 Guilford Pharmaceuticals Inc. Inhibitors of naaladase enzyme activity
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
IL134168A0 (en) 1997-08-14 2001-04-30 Hoffmann La Roche Heterocyclic vinylethers against neurological disorders
JP2001514181A (ja) * 1997-08-25 2001-09-11 ニューロゲン コーポレイション Ｇａｂａ脳レセプタリガンドとしての置換４−オキソ−ナフチリジン−３−カルボキサミド
AU771358B2 (en) 1997-11-21 2004-03-18 Astrazeneca Ab Metabotropic glutamate receptor antagonists for treating central nervous system diseases
AU2642699A (en) 1998-03-03 1999-09-20 Yamanouchi Pharmaceutical Co., Ltd. Remedies for brain infarction
BR9910130A (pt) 1998-04-17 2001-01-09 Kenneth Curry Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação
US20030216293A1 (en) 1998-07-07 2003-11-20 Tomas Eriksson Use of composition comprising at least one substance within the group GnRH-analogues for treatment of obsessive -compulsive disorder (OCD)
SE511005C2 (sv) 1998-07-07 1999-07-19 Laekartjaenster I Vaestsverige Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom
CA2345137A1 (en) 1998-10-02 2000-04-13 Novartis Ag Mglur5 antagonists for the treatment of pain and anxiety
GB9823847D0 (en) 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
GB9823845D0 (en) 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
EP1183238A1 (en) 1999-05-17 2002-03-06 Eli Lilly And Company Metabotropic glutamate receptor antagonists
NZ515894A (en) 1999-06-02 2003-09-26 Nps Pharma Inc Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
MXPA02000242A (es) 1999-06-30 2004-09-10 Prescient Neuropharma Inc Analogos de 2-aminoindano.
AU5667100A (en) 1999-07-02 2001-01-22 Prescient Neuropharma Inc. Novel aminoindanes
ES2198323T3 (es) 1999-07-06 2004-02-01 Eli Lilly And Company Profarmacos de diesteres de un acido decahidroisoquinolin-3-carboxilico.
AU5959900A (en) 1999-07-15 2001-02-05 Mcgill University Oligonucleotides for metabotropic glutamate receptor type 1 (mglur1)
CA2379918A1 (en) 1999-08-02 2001-02-08 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceuticals for neuropathic pain
DE60006618T2 (de) 1999-08-06 2004-09-23 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
WO2001010432A1 (en) * 1999-08-10 2001-02-15 Uab Research Foundation Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
SV2002000205A (es) 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
GB0005700D0 (en) 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
US20030008897A1 (en) 2000-03-17 2003-01-09 Mendel Carl M. Method of controlling weight gain associated with therapeutic drugs
US6455553B1 (en) * 2000-10-03 2002-09-24 Albert Einstein College Of Medicine Of Yeshiva University Method for treating a demyelinating condition
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
CA2442478C (en) 2001-04-02 2010-02-02 Mark F. Bear Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation
US6831077B2 (en) 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
CA2529318C (en) 2003-06-24 2013-09-17 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
PT1660440E (pt) * 2003-08-20 2012-05-15 Xenoport Inc Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
WO2006012403A1 (en) * 2004-07-20 2006-02-02 Massachusetts Institute Of Technology Methods of treatment: cell signaling and glutamate release
US20070254314A1 (en) 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
US20060058271A1 (en) 2004-09-16 2006-03-16 Geier Mark R Methods for screening, studying, and treating dissorders with a component of mercurial toxicity
US9095713B2 (en) * 2004-12-21 2015-08-04 Allison M. Foster Methods and systems for treating autism by decreasing neural activity within the brain
US20060264381A1 (en) * 2005-05-05 2006-11-23 Bear Mark F Methods of treating obsessive compulsive disorder
WO2007029063A2 (en) * 2005-07-29 2007-03-15 Ecole Polytechnique Federale De Lausanne (Epfl) Treatment and/or prevention of pervasive developmental disorders
WO2007050741A2 (en) * 2005-10-26 2007-05-03 Emory University Compositions for treating fragile x and other disorders methods of use thereof and screening for compounds for fragile x and other disorders
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20070191440A1 (en) * 2006-01-25 2007-08-16 Solomon Michael E Methods of treating autism and fragile X syndrome
EP2496224A1 (en) 2009-11-05 2012-09-12 Brown University Methods of treating elevations in mtor signaling

Also Published As

Publication number Publication date
US20130012587A1 (en) 2013-01-10
HUE032743T2 (en) 2017-10-30
US20120129940A1 (en) 2012-05-24
EP2083811A1 (en) 2009-08-05
US20130261186A1 (en) 2013-10-03
AU2007325836A1 (en) 2008-06-05
CY1118406T1 (el) 2017-06-28
PL2083811T3 (pl) 2017-05-31
LT2083811T (lt) 2017-01-25
EP2567696A1 (en) 2013-03-13
US8278276B2 (en) 2012-10-02
US20120122986A1 (en) 2012-05-17
CA2670116C (en) 2015-03-10
ES2610508T3 (es) 2017-04-27
US9044443B2 (en) 2015-06-02
US20130012586A1 (en) 2013-01-10
EP2083811B1 (en) 2016-10-26
EP2578216A1 (en) 2013-04-10
JP2010510314A (ja) 2010-04-02
US8273715B2 (en) 2012-09-25
DK2083811T3 (en) 2017-01-30
AU2007325836B2 (en) 2011-07-21
US20100029770A1 (en) 2010-02-04
US8143311B2 (en) 2012-03-27
PT2083811T (pt) 2017-01-23
SI2083811T1 (sl) 2017-02-28
HRP20170027T1 (hr) 2017-03-10
WO2008066750A1 (en) 2008-06-05
CA2670116A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
PL2083811T3 (pl) Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
EP2076326A4 (en) CE-ZR-R-O-CATALYSTS, ARTICLES WITH THE CE-ZR-R-O-CATALYSTS, AND METHOD FOR THE PRODUCTION AND USE OF THE CE-ZR-R-O-CATALYSTS
GB2434604B (en) Porous composites containing hydrocarbon-soluble well treatment agents and methods for using the same
EP1951263A4 (en) MULTITARGETING DISTURBING RNAS WITH TWO ACTIVE STRANDS AND DESIGN AND APPLICATION METHODS
EG26217A (en) Activated carbon impregnated with acid and a way to form
IL183963A0 (en) 1 - aminocyclohexane - derivatives for the treatment of multiple sclerosis, emotional liability and pseudobulbar affect
EP2078051A4 (en) PROCESS FOR PRODUCTION OF POLYSILOXANES AND USE THEREOF
HK1134679A1 (zh) 用於治療感染的組合物和方法
ZA200704677B (en) Compositions and methods for the treatment of autism
EP1845915A4 (en) SYSTEMS AND METHOD FOR TARGET HEAT TREATMENT
EP2012972A4 (en) STRUCTURED GRINDING AND PROCESS FOR ITS MANUFACTURE AND USE
EP1931601A4 (en) DENITRIFICATION PROCESS AND SYSTEM
ZA200807747B (en) Catalyst and hydrotreting process
EP2098200A4 (en) ABSORBENT ARTICLE AND ITS MANUFACTURING PROCESS
EP1912723A4 (en) GASQUENCY AND LAUNDRY EXTRACTION SYSTEM
IL195272A0 (en) Methods and compositions for the treatment of viral infections
IL188728A0 (en) Methods of treating epileptogenesis
ZA200805224B (en) Geopolymeric particles, fibers, shaped articles and methods of manufacture
HU0600668D0 (en) Active carrier, process for producing thereof and the use of thereof
TWI369732B (en) Semiconductor process and chamber used
EP1737445A4 (en) METHOD FOR TREATING DOWN SYNDROME
EP1905861A4 (en) PROCESS FOR FORMING ALUMINUM COATING FILM, ALUMINUM FIBER, AND GAS PROCESSING SYSTEM COMPRISING ALUMINUM FIBER
GB2435262B (en) Method, composition and articles
EP2085061A4 (en) METHOD OF MANUFACTURING ABSORBENT ARTICLE AND ABSORBENT ARTICLE
HK1118245A1 (en) Gas treatment adsorption-oxidation system